We examined if testicular cancer (TC) treatment is associated with any risk for cardiovascular morbidity or predicted mortality according to the SCORE model, in which a 10-year future risk of ≥5% for developing a fatal cardiovascular event qualify for high-risk status. One thousand one hundred thirty-four TC survivors treated 1980-1994 participated in this study (1998-2002). Patients were categorised in four treatment groups: surgery (n∈=∈225), radiotherapy (n∈=∈445), and two chemotherapy groups: cumulative cisplatin dose ≤850 mg (n∈=∈375) and >850 mg (cis>850, n∈=∈89). Patients with cardiovascular disease, diabetes or SCORE ≥5% constituted a high-risk group, and those with SCORE >1% an intermediate/high risk group. Age-adjusted mean SCORE was 0.93% for the surgery group. In comparison, chemotherapy treated patients had significantly higher SCORE (1.07%, p∈=∈0.01). Only 15% of patients were scored to be at high-risk, while 53% qualified for the intermediate/high risk group. Patients in the cis>850 group had increased odds for having intermediate/high risk, compared with the surgery group (OR 3.4, 95% CI 1.3-8.7). Only 23 cardiovascular events had occurred since the testicular cancer diagnosis. The SCORE model indicates that patients treated with cisplatin-based chemotherapy have a significantly increased future risk of a fatal cardiovascular event. TC survivors should be followed regularly with respect to cardiovascular risk profile beyond the routine 10-year clinical follow-up. © 2008 Springer Science+Business Media, LLC.
CITATION STYLE
Haugnes, H. S., Aass, N., Fosså, S. D., Dahl, O., Klepp, O., Wist, E. A., … Bremnes, R. M. (2008). Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. Journal of Cancer Survivorship, 2(3), 128–137. https://doi.org/10.1007/s11764-008-0054-1
Mendeley helps you to discover research relevant for your work.